Mitral valve replacement or repair and long-term risk of infective endocarditis: a Danish nationwide study: @ESC_Journals
🥸Nice study - mitral valve replacement and infective endocarditis during follow-up
👇👇👇
🥸1️⃣ This Danish nationwide cohort study examined the 10-year risk of first-time infective endocarditis (IE) in patients after mitral valve (MV) replacement or repair, compared to those at moderate risk of IE, using high-quality registry data from 2000–2020.
🥸2️⃣ The study included 1220 patients who underwent isolated MV replacement, 3239 who underwent MV repair, and 209,517 categorized as moderate risk of IE (such as those with CIEDs, congenital valve anomalies, HCM, rheumatic or degenerative valve disease).
Alcohol Use and Cardiovascular Disease: A Scientific Statement From the American Heart Association: @CircAHA
🥸 Great work from @AHAScience
😱 No level of alcohol is truly “safe”: Summary
👇👇👇
🥸1️⃣ Alcohol use and cardiovascular disease (CVD) have a complicated and often debated relationship; this AHA statement reviews decades of research on coronary artery disease (CAD), stroke, heart failure (HF), arrhythmias, and cardiomyopathy.
🥸2️⃣ Most evidence linking alcohol and CVD is observational, with strong risks for bias and confounding; randomized trials are rare, and definitive answers are lacking.
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity: @NEJM
🥸 SURMOUNT-5 Trial: Wow!
😱 Summary
👇👇👇
🥸 1️⃣ SURMOUNT-5 directly compares tirzepatide and semaglutide for obesity in adults without diabetes. First head-to-head randomized trial of these two GLP-1–based agents. Published @NEJM, May 2025.
[DOI: 10.1056/NEJMoa2416394]
🥸 2️⃣ 751 adults with BMI ≥30 or ≥27 + 1 comorbidity (HTN, dyslipidemia, OSA, or CVD) were randomized to tirzepatide (10 or 15 mg) or semaglutide (1.7 or 2.4 mg) once weekly for 72 weeks. No participants had type 2 diabetes.
Healthy ageing in older adults with cardiovascular disease: @ESC_Journals
🥸 So proud of Nathalie, Jon & @KritiKalra092 for their hard work
😱 With my friend @MichaelGNanna in published in the European Heart Journal
🥸What is healthy aging? How do we achieve it?
👇👇👇
🥸 1️⃣ Healthy ageing in cardiovascular disease matters because by 2050, adults 65+ will represent over 20% of the U.S. and nearly 30% of Europe's population, dramatically shifting healthcare needs.
🥸 2️⃣ Cardiovascular disease already leads all causes of death globally, and as populations age, CVD-related disability and healthcare costs will keep rising.
Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism: @NEJM
🥸 - good work #ACC25 @ACCinTouch
👇👇👇
🥸1️⃣ In cancer-associated VTE, extended anticoagulation is common—but the dose remains uncertain. The API-CAT trial tested reduced-dose vs. full-dose apixaban after 6 months of initial therapy.
🥸2️⃣ 1,766 patients with active cancer and prior VTE were randomized to apixaban 2.5 mg BID or 5 mg BID for 12 months. Median follow-up was nearly 12 months.
Global Effect of Cardiovascular Risk Factors on Lifetime Estimates: @NEJM
🥸 Great work from Germany on global life time risk of CVD risk
😱 Summary
👇👇👇
🥸1️⃣ Lifetime cardiovascular risk increases with the number of classic risk factors you carry at age 50. The Global Cardiovascular Risk Consortium analyzed over 2 million people to estimate how much risk factors shorten life and healthspan.
🥸2️⃣ Five risk factors were studied: high blood pressure, high cholesterol, diabetes, smoking, and unhealthy body weight.